Highlights Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
1.63 ^USD	+1.24%		+11.64%	+10.88%

Mar. 13	Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Mar. 13	Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q4 Revenue $73.5M, vs. Street Est of $18.6M	Mar. 13	MT
Spero Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections	Jan. 02	CI
Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q3 Revenue $25.5M, vs. Street Est of $15M	Nov. 13	MT
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q2 Revenue $2.7M, vs. Street Est of $1.08M	23-08-10	MT
Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Spero Therapeutics Announces Special Protocol Assessment Agreement with Fda for Phase 3 Pivot-Po Trial of Tebipenem Hbr	23-07-31	CI
Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q1 Revenue $2.1M	23-05-11	MT
Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q4 Revenue $47.4M, vs. Street Est of $22.9M	23-03-30	MT
Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q3 Revenue $2M	22-11-14	MT
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Spero Therapeutics Closes License Deal With GSK for Investigational Drug for Urinary Tract Infections	22-11-08	MT
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr	22-11-08	CI
Spero Therapeutics to Present Data at IDWeek 2022	22-10-19	CI
GSK plc and Spero Therapeutics, Inc. Announce Exclusive Licence Agreement for Tebipenem HBr	22-09-22	CI
GSK Receives Exclusive License for Spero Therapeutics' Oral Antibiotic Candidate	22-09-22	MT
GSK eyes Spero's experimental urinary tract infection drug, takes stake	22-09-22	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Highlights

Filters